Breakthrough or risk? FDA approves Alzheimer's drug
Reuters, 08 Jun 2021
U.S. regulators approved Biogen's aducanumab as the first treatment to attack a likely cause of Alzheimer's disease, despite controversy over the drug's effectiveness.
#News #Reuters #Biogen #aducanumab
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en